| Literature DB >> 25352839 |
Faham Khamesipour1, Hassan Momtaz2, Morteza Azhdary Mamoreh3.
Abstract
A total of 30 Pasteurella multocida strains isolated from 333 pneumonic and apparently health slaughter cattle were examined for capsule biosynthesis genes and 23 virulence-associated genes by polymerase chain reaction (PCR). The disc diffusion technique was used to determine antimicrobial resistance profiles among the isolates. Of the isolates, 23 belonged to capsular type A, 5 to capsular type D and two isolates were untypeable. The distribution of the capsular types in pneumonic lungs and in apparently health lungs was statistically similar. All virulence genes tested were detected among the isolates derived from pneumonic lungs; whereas isolates derived from apparently health lungs carried 16 of the 23 genes. The frequently detected genes among isolates from pneumonic lungs were exbD, hgbA, hgbB, ompA, ompH, oma87, and sodC; whereas tadD, toxA, and pmHAS genes occurred less frequently. Most of the adhesins and superoxide dismutases; and all of the iron acquisition and protectin proteins occurred at significantly (p ≤ 0.05) higher frequencies in isolates from pneumonic lungs. Isolates from apparently healthy lungs didn't carry the following genes; hsf-1, hsf-2, tadD, toxA, nanB, nanH, and pmHAS. One adhesion (hsf-1) and two iron acquisition (exbD and tonB) genes occurred at significantly (p ≤ 0.05) higher frequencies among capA isolates. All the P. multocida isolates were susceptible to ciprofloxacin, co-trimoxazole, doxycycline, enrofloxacin, nitrofurantoin, and tetracyclines. Different proportions of the isolates were however resistant to ampicillin, amoxicillin, erythromycin, lincomycin, penicillin, rifampin, streptomycin, and florfenicol. Our results reveal presence of virulence factors (VFs) in P. multocida strains isolated from symptomatic and asymptomatic bovids. A higher frequency of the factors among isolates from symptomatic study animals may suggest their role in pathogenesis of P. multocida-associated bovine respiratory disease (BRD). The results further reveal occurrence of antimicrobial resistance among some isolates. Control strategies for this pathogen, which could include development of an effective vaccine, are warranted so as to mitigate the social and economic consequences attributable to natural infections with this bacterium.Entities:
Keywords: Iran; Pasteurella multocida; antimicrobial resistance; cattle; virulence factors
Year: 2014 PMID: 25352839 PMCID: PMC4196553 DOI: 10.3389/fmicb.2014.00536
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Primers used for the detection of serogroups in strains of .
| All | KMT1 | KMT1T7 KMT1SP6 | ATCCGCTATTTACCCAGTGG GCTGTAAACGAACTCGCCAC | 460 | 55 | Townsend et al., |
| Capsular type A | hyaD-hyaC | CAPA-F CAPA-R | CATTTATCCAAGCTCCACC GCCCGAGAGTTTCAATCC | 760 | 55 | |
| Capsular type D | DcbF | CAPD-F CAPD-R | TTACAAAAGAAAGACTAGGAGCCC CATCTACCCACTCAACCATATCAG | 657 | 55 |
Tested virulence-associated genes in strains of .
| ptfA | Type 4 fimbriae |
| fimA | Fimbriae (from Pm70) |
| hsf-1 | Autotransporter adhesion (from Pm70) |
| hsf-2 | Autotransporter adhesion (from Pm70) |
| pfhA | Filamentous hemagglutinin |
| tadD | Putative non-specific tight adherence protein D |
| toxA | Dermonecrotic toxin |
| exbB | Accessory protein Ton-dependent transport of iron compounds |
| exbD | Accessory protein Ton-dependent transport of iron compound |
| tonB | Iron transporters, transport ferric-siderophore complexes |
| hgbA | A hemoglobin-binding protein |
| hgbB | B hemoglobin-iron uptake |
| Fur | Ferric uptake regulation protein |
| nanB | Outer membrane-associated proteins, an autotransporter protein |
| nanH | Outer membrane-associated proteins, small sialidases |
| pmHAS | Hyaluronan synthase |
| sodA | Superoxide dismutase |
| sodC | Superoxide dismutase |
| tbpA | Superoxide dismutase |
| ompA | Outer membrane protein A |
| ompH | Outer membrane protein H |
| oma87 | Outer membrane protein 87 |
| plpB | Lipoprotein B |
Primers used for the detection of virulence-associated genes in strains of .
| ptfA | TGTGGAATTCAGCATTTTAGTGTGTC TCATGAATTCTTATGCGCAAAATCCT GCTGG | 488 | 55 | Townsend et al., |
| fimA | CCATCGGATCTAAACGACCTA AGTATTAGTTCCTGCGGGTG | 866 | 55 | |
| hsf-1 | TTGAGTCGGCTGTAGAGTTCG ACTCTTTAGCAGTGGGGACAACCTC | 654 | 54 | |
| hsf-2 | ACCGCAACCATGCTCTTAC TGACTGACATCGGCGGTAC | 433 | 54 | |
| pfhA | TTCAGAGGGATCAATCTTCG AACTCCAGT TGGTTTGTCG | 286 | 55 | |
| tadD | TCTACCCATTCTCAGCAAGGC ATCATTTCGGGCATTCACC | 416 | 55 | |
| toxA | CTTAGATGAGCGACAAGG GAATGCCACACCTCTATAG | 864 | 55 | Townsend et al., |
| sodA | TACCAGAATTAGGCTACGC GAAACGGGTTGCTGCCGCT | 361 | 55 | Ewers et al., |
| tbpA | TTGGTTGGAAACGGTAAAGC TAACGTGTACGGAAAAGCCC | 728 | 54 | |
| sodC | AGTTAGTAGCGGGGTTGGCA TGGTGCTGGGTGATCATCATG | 235 | 55 | Lainson et al., |
| nanB | CATTGCACCTAACACCTCT GGACACTGATTGCCCTGAA | 555 | 55 | Townsend et al., |
| nanH | GTGGGAACGGGAATTGTGA ACATGCCAAGTTTGCCCTA | 287 | 55 | |
| ompA | CGCATAGCACTCAAGTTTCTCC CATAAACAGATTGACCGAAACG | 201 | 55 | Townsend et al., |
| ompH | CGCGTATGAAGGTTTAGGT TTTAGATTGTGCGTAGTCAAC | 438 | 55 | |
| oma87 | GGCAGCGAGCAACAGATAACG TGTTCGTCAAATGTCGGGTGA | 838 | 55 | |
| plpB | TTTGGTGGTGCGTATGTCTTCT AGTCACTTTAGATTGTGCGTAG | 282 | 55 | |
| pmHAS | TCAATGTTTGCGATAGTCCGTTAG TGGCGAATGATCGGTGATAGA | 430 | 54 | Townsend et al., |
| exbB | TTGGCTTGTGATTGAACGC TGCAGGAATGGCGACTAA A | 283 | 55 | Townsend et al., |
| exbD | CGTTCTGATTACAGCCTCTT AACGAAATCTTGGAAACTGG | 247 | 55 | |
| tonB | CGACGGTGAAACCTGAGCCA CCGAGCGATAAGCATTGACT | 261 | 55 | |
| hgbA | TCAACGGCAGATAATCAGGG GCGGGAATGCTGAAGATAAG | 267 | 55 | |
| Fur | GTTTACCGTGTATTAGACCA CATTACTACATTTGCCATAC | 244 | 55 | |
| hgbB | ACCGCGTTGGAATTATGATTG CATTGAGTACGGCTTGACAT | 788 | 55 | Ewers et al., |
Prevalence of .
| Pneumonic lungs | 219 | 25 (11.4%) |
| Healthy lungs | 114 | 5 (4.4%) |
| Total | 333 | 30 (9.0%) |
Distribution of capsular serotypes among the isolates.
| Type A | 23 (76.7%) | 18 (72.0%) | 5 (100.0%) |
| Type D | 5 (16.7%) | 5 (20.0%) | – |
| Untyped | 2 (6.7%) | 2 (8.0%) | – |
Capsular types and virulence genes detected among .
| 1 | Type A | |
| 2 | Type A | |
| 3 | Type A | |
| 4 | Type D | |
| 5 | Type D | |
| 6 | Untyped | |
| 7 | Type A | |
| 8 | Type A | |
| 9 | Type A | |
| 10 | Type A | |
| 11 | Type D | |
| 12 | Type A | |
| 13 | Type A | |
| 14 | Type A | |
| 15 | Type A | |
| 16 | Type D | |
| 17 | Type A | |
| 18 | Type A | |
| 19 | Type A | |
| 20 | Type A | |
| 21 | Untyped | |
| 22 | Type A | |
| 23 | Type A | |
| 24 | Type A | |
| 25 | Type A | |
| 26 | Type D | |
| 27 | Type A | |
| 28 | Type A | |
| 29 | Type A | |
| 30 | Type A |
Distribution of VFs according to associated VF genes.
| 24 (80.0%) | 23 (92.0%) | 1 (20.0%) | |
| 24 (80.0%) | 23 (92.0%) | 1 (20.0%) | |
| 18 (60.0%) | 18 (72.0%) | – | |
| 23 (76.7%) | 23 (92.0%) | – | |
| 18 (60.0%) | 15 (60.0%) | 3 (60.0%) | |
| 12 (40.0%) | 12 (48.0%) | – | |
| 3 (10.0%) | 3 (12.0%) | – | |
| 25 (83.3%) | 24 (96.0%) | 1 (20.0%) | |
| 26 (86.7%) | 25 (100.0%) | 1 (20.0%) | |
| 25 (83.3%) | 24 (96.0%) | 1 (20.0%) | |
| 26 (86.7%) | 25 (100.0%) | 1 (20.0%) | |
| 28 (93.3%) | 25 (100.0%) | 3 (60.0%) | |
| 25 (83.3%) | 24 (96.0%) | 1 (20.0%) | |
| 25 (83.3%) | 25 (100.0%) | – | |
| 24 (80.0%) | 24 (96.0%) | – | |
| 10 (33.3%) | 10 (40.0%) | – | |
| 27 (90.0%) | 25 (100.0%) | 2 (40.0%) | |
| 26 (86.7%) | 25 (100.0%) | 1 (20.0%) | |
| 27 (90.0%) | 25 (100.0%) | 2 (40.0%) | |
| 25 (83.3%) | 24 (96.0%) | 1 (20.0%) | |
| 25 (83.3%) | 24 (96.0%) | 1 (20.0%) | |
| 26 (86.7%) | 25 (100.0%) | 1 (20.0%) | |
| 20 (66.7%) | 18 (72.0%) | 2 (40.0%) | |
Distribution of VFs according to capsule serotypes among 30 bovine isolates of .
| 24 (80.0%) | 19 (82.6%) | 5 (100.0%) | – | |
| 24 (80.0%) | 20 (87.0%) | 3 (60.0%) | 1 (50.0%) | |
| 18 (60.0%) | 18 (78.3%) | – | – | |
| 23 (76.7%) | 18 (78.3%) | 5 (100.0%) | – | |
| 18 (60.0%) | 13 (56.5%) | 4 (80.0%) | 1 (50.0%) | |
| 12 (40.0%) | 10 (43.5%) | 2 (40.0%) | – | |
| 3 (10.0%) | 3 (13.0%) | – | – | |
| 25 (83.3%) | 19 (82.6%) | 5 (100.0%) | 1 (50.0%) | |
| 26 (86.7%) | 23 (100.0%) | 3 (60.0%) | – | |
| 25 (83.3%) | 23 (100.0%) | – | 2 (100.0%) | |
| 26 (86.7%) | 20 (87.0%) | 5 (100.0%) | 1 (50.0%) | |
| 28 (93.3%) | 23 (100.0%) | 5 (100.0%) | – | |
| 25 (83.3%) | 19 (82.6%) | 5 (100.0%) | 1 (50.0%) | |
| 25 (83.3%) | 19 (82.6%) | 5 (100.0%) | 1 (50.0%) | |
| 24 (80.0%) | 18 (78.3%) | 4 (80.0%) | 2 (100.0%) | |
| 10 (33.3%) | 8 (34.8%) | 2 (40.0%) | – | |
| 27 (90.0%) | 20 (87.0%) | 5 (100.0%) | 2 (100.0%) | |
| 26 (86.7%) | 21 (91.3%) | 3 (60.0%) | 2 (100.0%) | |
| 27 (90.0%) | 21 (91.3%) | 5 (100.0%) | 1 (50.0%) | |
| 25 (83.3%) | 18 (78.3%) | 5 (100.0%) | 2 (100.0%) | |
| 25 (83.3%) | 23 (100.0%) | 2 (40.0%) | – | |
| 26 (86.7%) | 23 (100.0%) | 3 (60.0%) | – | |
| 20 (66.7%) | 18 (78.3%) | 1 (20.0%) | 1 (50.0%) | |
Antimicrobial resistance profiles of .
| Ampicillin | 10 (33.3%) | 11 (36.7%) | 9 (30.0%) |
| Amikacin | 0 (0.0%) | 1 (3.3%) | 29 (96.7%) |
| Cloramphenicol | 0 (0.0%) | 0 (0.0%) | 29 (96.7%) |
| Carbenicillin | 0 (0.0%) | 1 (3.3%) | 29 (96.7%) |
| Ciprofloxacin | 0 (0.0%) | 0 (0.0%) | 30 (100.0%) |
| Co-trimoxazole | 0 (0.0%) | 0 (0.0%) | 30 (100.0%) |
| Doxycycline | 0 (0.0%) | 0 (0.0%) | 30 (100.0%) |
| Enrofloxacin | 0 (0.0%) | 0 (0.0%) | 30 (100.0%) |
| Gentamicin | 0 (0.0%) | 1 (3.3%) | 29 (96.7%) |
| Lincomycin | 13 (43.3%) | 8 (26.7%) | 8 (26.7%) |
| Nitrofurantoin | 0 (0.0%) | 0 (0.0%) | 30 (100.0%) |
| Oxytetracycline | 0 (0.0%) | 0 (0.0%) | 30 (100.0%) |
| Penicillin | 12 (40.0%) | 9 (30.0%) | 9 (30.0%) |
| Rifampin | 6 (20.0%) | 6 (20.0%) | 18 (60.0%) |
| Streptomycin | 5 (16.7%) | 0 (0.0%) | 25 (83.3%) |
| Tetracycline | 0 (0.0%) | 0 (0.0%) | 30 (100.0%) |
| Amoxicillin | 3 (10.0%) | 3 (10.0%) | 24 (80.0%) |
| Erythromycin | 10 (33.3%) | 10 (33.3%) | 10 (33.3%) |
| Kanamycin | 0 (0.0%) | 4 (13.3%) | 26 (86.7%) |
| Florfenicol | 5 (16.7%) | 6 (20.0%) | 19 (63.3%) |